{
    "clinical_study": {
        "@rank": "50309", 
        "arm_group": [
            {
                "arm_group_label": "Placebo fasting", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Single or multiple dosing placebo"
            }, 
            {
                "arm_group_label": "Active fed condition", 
                "arm_group_type": "Experimental", 
                "description": "AZD0914 given as single dose"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the safety and tolerability of orally administered\n      AZD0914 in healthy adult subjects."
        }, 
        "brief_title": "A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD0914", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "condition": "Gonococcal (GC) Infection", 
        "condition_browse": {
            "mesh_term": "Gonorrhea"
        }, 
        "detailed_description": {
            "textblock": "A Phase I, Randomized, Placebo-controlled, Single-center Study to Assess the Safety,\n      Tolerability, and Pharmacokinetics of AZD0914 After a Single Oral Administration and to\n      Assess the Effect of Food in Healthy Adult Volunteers"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male and female (of non-childbearing potential)subjects  aged 18 to55 years\n             (inclusive).\n\n          -  Have a body mass index (BMI) between 18.00 and 30.50 kg/m2 and weigh at least 50 kg\n             and no more than 100 kg\n\n          -  Male subjects should be willing to use barrier contraception, ie, condoms, from the\n             day of dose administration until at least 3 months after dose administration of the\n             IP\n\n        Exclusion Criteria:\n\n          -  History of any important clinically significant disease or disorder which, in the\n             opinion of the PI, may either put the subject at risk because of participation in the\n             study, or influence the results or the subject's ability to participate in the study\n\n          -  History or presence of gastrointestinal, hepatic or renal disease or any other\n             condition known to interfere with absorption, distribution, metabolism, or excretion\n             of drugs\n\n          -  Any clinically important illness, medical/surgical procedure, or trauma within 4\n             weeks from the first administration of IP as judged by the PI\n\n          -  History of gastrointestinal ulcer disease, inflammatory bowel disease, indigestion\n             symptoms >3 times a week, or blood in stool in previous 6 months not related to anal\n             trauma"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01929629", 
            "org_study_id": "D4930C00001"
        }, 
        "intervention": [
            {
                "arm_group_label": "Placebo fasting", 
                "description": "Single ascending doses", 
                "intervention_name": "Part A", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Active fed condition", 
                "description": "Single doses food effect. Subjects to receive 2 single doses, one in fed and one in fasted.", 
                "intervention_name": "Part B", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Phase 1", 
            "Healthy Volunteers", 
            "First Time in Man", 
            "Pharmacokinetics"
        ], 
        "lastchanged_date": "April 14, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Overland Park", 
                    "country": "United States", 
                    "state": "Kansas"
                }, 
                "name": "Research Site"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase I, Randomized, Placebo-controlled, Single-center Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD0914 After a Single Oral Administration and to Assess the Effect of Food in Healthy Adult Volunteers", 
        "overall_official": [
            {
                "affiliation": "Quintiles Phase I unit, Kansas", 
                "last_name": "David Mathews, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "AstraZeneca", 
                "last_name": "Humphrey Gardener, MD", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Applies to Part A and B", 
            "measure": "Description of the safety profile in terms of adverse events; blood pressure, heart rate and body temperature; electrocardiograms; telemetry; clinical chemistry ; haematology and physical examination", 
            "safety_issue": "Yes", 
            "time_frame": "From admission on day -1 until follow up. ( Max 16 days)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01929629"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Description of pharmacokinetics(PK) for AZD0914 study part A and B in terms of maximum observed plasma concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "Samples taken at predose, and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 36, 48, and 72 hours postdose"
            }, 
            {
                "measure": "Description of pharmacokinetics(PK) for AZD0914 study part A and B in terms of time to reach maximum observed plasma concentration (tmax)", 
                "safety_issue": "No", 
                "time_frame": "Samples taken at predose, and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 36, 48, and 72 hours postdose"
            }, 
            {
                "measure": "Description of pharmacokinetics(PK) for AZD0914(Part A and B) in terms of AUC from time zero to time of last quantifiable AZD0914 concentration [AUC(0-last)]", 
                "safety_issue": "No", 
                "time_frame": "Samples taken at predose, and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 36, 48, and 72 hours postdose"
            }, 
            {
                "measure": "Description of pharmacokinetics(PK) for AZD0914(Part A and B) in terms of AUC from time zero to 24 hours after dosing [AUC(0-24)]", 
                "safety_issue": "No", 
                "time_frame": "Samples taken at predose, and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 36, 48, and 72 hours postdose"
            }, 
            {
                "measure": "Description of pharmacokinetics(PK) for AZD0914(Part A and B) in terms of terminal half-life (t1/2\u03bbz) and apparent plasma clearance (CL/F)", 
                "safety_issue": "No", 
                "time_frame": "Samples taken at predose, and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 36, 48, and 72 hours postdose"
            }, 
            {
                "measure": "Description of pharmacokinetics(PK) for AZD0914(Part A and B) in terms of apparent terminal phase volume of distribution (Vz/F), and at steady state (Vss/F),mean residence time", 
                "safety_issue": "No", 
                "time_frame": "Samples taken at predose, and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 36, 48, and 72 hours postdose"
            }, 
            {
                "measure": "Description of pharmacokinetics(PK) for AZD0914 (Part A and B) in terms of cumulative amount of investigation product (IP) excreted unchanged into urine from zero to time t [Ae(0-t)],", 
                "safety_issue": "No", 
                "time_frame": "Samples taken from collections between -12 to 0 hours predose, and 0 to 4, 4 to 8, 8 to 12, 12 to 24, 24 to 48, and 48 to 72 hours after the 1st dose"
            }, 
            {
                "measure": "Description of pharmacokinetics(PK) for AZD0914 (Part A and B) in terms of fraction of dose excreted unchanged into urine (fe), and renal clearance (CLr)", 
                "safety_issue": "No", 
                "time_frame": "Samples taken from collections between -12 to 0 hours predose, and 0 to 4, 4 to 8, 8 to 12, 12 to 24, 24 to 48, and 48 to 72 hours after the 1st dose"
            }
        ], 
        "source": "AstraZeneca", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}